arrow
M

Marco Russano

Fondazione Policlinico Universitario Campus Bio-Medico
H指数:24
被引数:2,941

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Chemotherapy Backbone and Outcomes of Immune Checkpoint Inhibitor Combinations Across Solid Tumors: A Pan-Tumor Network Meta-Analysis

化疗基础方案与免疫检查点抑制剂联合疗法在实体瘤中的疗效:一项泛肿瘤网络Meta分析

2026-09-170
OAAI
Skeletal metastatic burden as a strong prognostic factor of survival in advanced NSCLC treated with chemo-immunotherapy: An exploratory imaging-based analysis

骨转移负荷作为接受化疗-免疫治疗晚期非小细胞肺癌生存的强预后因素:一项基于影像学的探索性分析

2026-08-010
OAAI
A multicenter prospective study of single nucleotide polymorphisms in the PDCD1 (programmed cell death 1) gene in patients with metastatic lung adenocarcinoma treated with pembrolizumab

一项关于接受帕博利珠单抗治疗的转移性肺腺癌患者中PDCD1(programmed cell death 1)基因单核苷酸多态性的多中心前瞻性研究

2026-04-050
OAAI
Family history enrichment in Non-Small cell Lung Cancer: A cross-sectional − prospective study to inform referral for germline testing

非小细胞肺癌中的家族史信息补充:一项用于指导胚系检测转诊的横断面-前瞻性研究

2026-02-260
OAAI
Real-world effectiveness and safety of first-line chemoimmunotherapy combinations in metastatic non-small cell lung cancer with programmed death ligand-1 < 50%: results from an Italian observational study

PD-L1低表达转移性非小细胞肺癌一线化疗联合免疫治疗方案的疗效与安全性:一项意大利观察性研究的结果

2025-07-120
OAAI
Dose dependent detrimental effect of baseline pantoprazole on clinical outcomes from first-line chemo-ICI regimens in patients with advanced stage NSCLC

基线泮托拉唑对晚期NSCLC患者一线化疗联合免疫检查点抑制剂方案临床结局的剂量依赖性有害影响

2024-09-010
PRE
Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO)

奥希替尼在具有罕见表皮生长因子受体突变的非小细胞肺癌中的活性: 回顾性观察性多中心研究 (ARTICUNO)

2024-06-011
OAAI
APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research
2024-03-011
OAAI
Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario
2022-04-0145
OAAI
Evaluation of COVID-19 impact on DELAYing diagnostictherapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario (vol 7, 100406, 2022)
2022-04-012
OAAI
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status
2022-01-215
OAAI
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort

生命晚期的PD-1/PD-L1检查点抑制剂: 来自大型多中心队列的临时分析

2021-06-2415
OAAI
Post-progression outcomes of NSCLC patients with PD-L1 expression > 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study

在一项大型多中心真实世界研究中接受一线单药pembrolizumab治疗的PD-L1表达> 50% 的NSCLC患者的进展后结局

2021-05-0120
OAAI